{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:32:28Z","timestamp":1790645548972,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Pulm. circ."],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Dasatinib and other tyrosine kinase inhibitors are commonly utilized in the management of chronic myelogenous leukemia. Pulmonary hypertension is an important adverse event associated with dasatinib. Mechanisms for pulmonary hypertension include pulmonary endothelial injury, apoptosis, and increased susceptibility to other triggers for pulmonary hypertension. The diagnosis is suspected based on symptoms, suggested by echocardiographic findings, and confirmed with right heart catheterization. Management includes discontinuation of dasatinib and initiation of pulmonary vasodilators. Persistent pulmonary hypertension is present in up to one third of patients after cessation of dasatinib. Other tyrosine kinase inhibitors, including bosutinib, lapatinib, and ponatinib have also been implicated in pulmonary hypertension in small series, although evidence for causation is less robust. A high index of suspicion, continued vigilance for pulmonary hypertension with long\u2010term use, and early therapy are important in optimizing outcomes in this population.<\/jats:p>","DOI":"10.1177\/2045894019865704","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T05:21:50Z","timestamp":1562304110000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":37,"title":["Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors"],"prefix":"10.1002","volume":"9","author":[{"given":"Ashraf","family":"El\u2010Dabh","sequence":"first","affiliation":[{"name":"Guthrie Robert Packer Hospital Sayre USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9635-0798","authenticated-orcid":false,"given":"Deepak","family":"Acharya","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease School of Medicine University of Arizona Tucson USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","unstructured":"Authors\/Task Force M Galie N Humbert M et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) International Society for Heart and Lung Transplantation (ISHLT).Eur Heart J2015; 37(1): 67\u2013119.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.029"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau G","year":"2019","journal-title":"Eur Respir J"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2017.02.016"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1460"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"e_1_2_12_8_1","unstructured":"US National Library of medicine clinicaltrials.gov search.https:\/\/http:\/\/www.clinicaltrials.gov\/ct2\/results?term=dasatinib&Search=Apply&age_v=&gndr=&type=&rslt=(accessed 13 April 2019)."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24174"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003889"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.9597"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00091912"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.13.9620"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00154210"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86249"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00537"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02472-2018","article-title":"Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance\u2010pharmacodynamic study","volume":"53","author":"Cornet L","year":"2019","journal-title":"Eur Respir J"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00217-2017","article-title":"Long\u2010term outcomes of dasatinib\u2010induced pulmonary arterial hypertension: a population\u2010based study","volume":"50","author":"Weatherald J","year":"2017","journal-title":"Eur Respir J"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01694-2017","article-title":"First histopathological evidence of irreversible pulmonary vascular disease in dasatinib\u2010induced pulmonary arterial hypertension","volume":"51","author":"Daccord C","year":"2018","journal-title":"Eur Respir J"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.7472"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.08.007"},{"key":"e_1_2_12_25_1","unstructured":"Administration Food and Drug. FDA drug safety communication: sprycel (dasatinib) and risk of pulmonary arterial hypertension 2011.https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010drug\u2010safety\u2010communication\u2010sprycel\u2010dasatinib\u2010and\u2010risk\u2010pulmonary\u2010arterial\u2010hypertension. (accessed 13 April 2019)."},{"key":"e_1_2_12_26_1","unstructured":"Dasatinib prescribing label.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf. (accessed 13 April 2019)."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.415"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035913"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.02692"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.09.026"},{"key":"e_1_2_12_31_1","first-page":"89","article-title":"Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib","volume":"3","author":"Swords R","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_12_32_1","first-page":"999","article-title":"Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia","volume":"57","author":"Morishita S","year":"2016","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200707-1037OC"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.11030554"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24838"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2016.03.002"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01410-2016"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217733444"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01110-2015"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1103-0"},{"key":"e_1_2_12_42_1","unstructured":"Efficacy Safety Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01179737. (accessed 13 April 2019)."},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01004-2016"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14608"}],"container-title":["Pulmonary Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2045894019865704","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1177\/2045894019865704","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2045894019865704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:14:28Z","timestamp":1693199668000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1177\/2045894019865704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1177\/2045894019865704"],"URL":"https:\/\/doi.org\/10.1177\/2045894019865704","archive":["Portico"],"relation":{},"ISSN":["2045-8940","2045-8940"],"issn-type":[{"value":"2045-8940","type":"print"},{"value":"2045-8940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}